Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that Health Canada has authorized Vabysmo® (faricimab injection) for use in a 6.0 mg single-use pre-filled syringe (PFS) for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion (RVO).1 These leading causes of vision loss affect around 70 million people worldwide and can have a serious impact on patients, their families, and caregivers.
Supply for Vabysmo PFS will become available to Canadian ophthalmologists and their patients in the coming months. Roche Canada is committed to continuing to work with the provincial and territorial jurisdictions to make Vabysmo PFS available as soon as possible through public and private drug plans for the patients who need it.
Vabysmo is the first and only bispecific antibody approved for the eye and has demonstrated rapid and robust vision improvements and retinal drying in wet AMD, DME and RVO.1,6,7,8 Retinal drying is an important clinical measure, as swelling from excess fluid in the back of the eye is associated with distorted and blurred vision.9 This was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluid
